Incyte (United States)

Recent papers from Incyte (United States)

1. Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trialsNature Medicine · 2026
2. Advancing Evidence Generation in Small, Diverse, Understudied PopulationClinical Pharmacology & Therapeutics · 2026
3. Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D MutantJournal of Medicinal Chemistry · 2026
4. Exploring How Healthcare Professionals Diagnose and Manage Vitiligo: Global VALIANT Study Findings and RecommendationsDermatology and Therapy · 2026
5. Discovery of Pyrazolopyrimidines as Potent and Orally Bioavailable MRGPRX2 AntagonistsACS Medicinal Chemistry Letters · 2026
6. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trialThe Lancet · 2025
7. Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 InhibitorDermatology and Therapy · 2026
8. Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action StudyJournal of Investigative Dermatology · 2026
9. Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2Journal of Medicinal Chemistry · 2026
10. Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen PlanusJAMA Dermatology · 2026
11. Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United StatesJournal of Dermatological Treatment · 2026
12. Prevalence and emotional valence of genital responses related to sexual abuse memories in patients with PTSDEuropean journal of psychotraumatology · 2026
13. Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medicationsHematology · 2026
14. RefactorBench-JS: Evaluating LLM Agents on Behavior-Preserving Code Decomposition2026
15. Skin and Plasma Pharmacokinetics of Povorcitinib After Oral Administration in Healthy Participants: An Open-Label, Multiple-Dose Phase 1 StudyJID Innovations · 2026
16. Online-delivered eye movement desensitization and reprocessing treatment for adults with post-traumatic stress disorder due to multiple traumas: a non-concurrent multiple baseline designEuropean journal of psychotraumatology · 2026
17. EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE StudyDermatology and Therapy · 2026
18. High-Precision Detection of Homona magnanima and Adoxophyes honmai in Mandarin Orchards Using Deep LearningACS Agricultural Science & Technology · 2026
19. A theory-driven rationale for EMDR therapy among patients with a personality disorderFrontiers in Psychology · 2026
20. Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of PovorcitinibDermatology and Therapy · 2026